Pharvaris PHVS 深 滬
已收盤 08-07 16:00:00 美东时间
34.91
+0.460
+1.34%
華盛通- 最 高35.77
- 今 開35.00
- 成交量 69.64万股
- 最 低 34.45
- 昨 收 34.45
- 總市值 24.19亿
- 52周最高 36.60
- 市盈率 靜 --
- 換手率 1.01%
- 52周最低 20.65
- 委 比 77.78%
- 總股本 6928.25万
- 歷史最高 42.86
- 量 比 1.77
- 振 幅 3.83%
- 歷史最低 1.77
- 每 手 1
- 風險率 3.83%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
Pharvaris announced results from a qualitative study published in *Frontiers in Immunology* assessing the experiences of people with acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). The study highlights the significant burden of the disease, including frequent misdiagnoses, painful attacks, and wide-ranging impact on patients' lives. Findings informed the design and endpoint selection of the ongoing Phase 3 CREAATE study (NCT072668...
08-06 10:50
Oppenheimer’s ‘best of the best’ momentum list: NVDA, LRCX and more
Nvidia (NVDA) and Lam Research (LRCX) are among the largest names on Oppenheimer’s latest “best of the best” momentum screen. Oppenheimer’s technical analysis team said the list provides technical col...
07-20 03:10
美股大行评级 | 潜在涨幅284.62%！Annexon获Needham上调目标价至25美元；多家大行上调美国银行目标价
今日重点评级关注：Needham：维持Annexon"买入"评级，目标价从11美元升至25美元；Benchmark：维持Prenetics Global"买入"评级，目标价从30美元升至40美元
07-16 18:55
Wells Fargo Initiates Coverage On Pharvaris with Overweight Rating, Announces Price Target of $55
Wells Fargo analyst Yanan Zhu initiates coverage on Pharvaris (NASDAQ:PHVS) with a Overweight rating and announces Price Target of $55.
07-15 19:03
Pharvaris Says FDA Accepts NDA For Deucrictibant IR Capsule (20 Mg) For On-Demand Treatment Of Hereditary Angioedema Attacks; PDUFA Target Action Date Set April 23, 2027
If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacks NDA includes positive data from successful clinical program demonstrating rapid relief and sustained response to resolution of HAE attack symptoms and a well-tolerated safety profile PDUFA action...
07-06 18:53
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
Pharvaris announced the FDA acceptance of its NDA for deucrictibant IR capsule for on-demand treatment of HAE attacks. If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist for HAE. The NDA includes positive clinical data showing rapid relief and sustained response, with a well-tolerated safety profile. The PDUFA action date is set for April 23, 2027. Deucrictibant has been granted orphan drug designation in the U.S....
07-06 10:50
美股大行评级 | 潜在涨幅135.66%！Ocular Therapeutix获Chardan Capital升目标价至23美元，维持"买入"评级
今日重点评级关注：Chardan Capital：维持Ocular Therapeutix"买入"评级，目标价从21美元升至23美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从30美元升至40美元
06-26 17:42
Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $46
Morgan Stanley analyst Matthew Harrison maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $41 to $46.
06-26 01:33
Pharvaris Highlights New Deucrictibant Data at EAACI 2026, Says HAE Treatment Data Support On-Demand and Preventive Use
Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), ...
06-15 18:52
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
